

Press release

25 August, 2023

## **Curasight to present at HC Andersen Capital and at HC Andersen Life Science seminar**

**Copenhagen, Denmark, 25 August 2023 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company's Interim Report Q2 2023 at HC Andersen Capital 30 August and the clinical progress at HC Andersen Capital Life Science seminar, 31 August 2023.**

The presentations will include an update on the business progress made by the company during the first half of 2023 and look ahead at the coming news flow expected in rest of 2023. Management will give an overall update on the company's pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain and prostate cancer besides the newly signed global partnership agreement with Curium.

**The HC Andersen Capital presentation of the company's Interim Report Q2 2023 will be webcasted live 13:00 - 13:30 (CET), Wednesday 30 August 2023.**

An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight's website, after the presentation is completed.

For more information – please [click here](#)

**The HC Andersen Capital Life Science seminar will be webcasted live 11:30 - 11:55 (CET), Thursday 31 August 2023.**

An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight's website, after the presentation is completed.

For more information – please [click here](#)

**For more information regarding Curasight, please contact:**

Ulrich Krasilnikoff, CEO  
Phone: +45 22 83 01 60  
E-mail: [uk@curasight.com](mailto:uk@curasight.com)  
[www.curasight.com](http://www.curasight.com)

---

**Curasight** is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.